Lisa Rhyne, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 372 North Faler, Pinedale, WY 82941 Phone: 307-367-6236 |
Mrs. Sarah Lynn Langseth, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 317 N Faler Avenue, Pinedale, WY 82941 Phone: 307-367-6236 Fax: 307-367-3332 |
Cassandra D Bennett, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 317 N Faler Ave, Pinedale, WY 82941 Phone: 307-367-6236 Fax: 307-367-3332 |
Mrs. Virginia Helene Mika, MSOTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 317 N Faler Ave, Pinedale, WY 82941 Phone: 307-367-6236 Fax: 307-367-3332 |
Jilda Senatore Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 191 South Franklin, Pinedale, WY 82941 Phone: 307-367-6306 |
News Archive
Gently rocking embryos while they grow during in vitro fertilization (IVF) improves pregnancy rates in mice by 22 percent, new University of Michigan research shows. The procedure could one day lead to significantly higher IVF success rates in humans.
Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Oncura, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds. Oncura is a unit of GE Healthcare. Under the terms of the agreement, Theragenics will be the exclusive palladium-103 seed supplier to Oncura, subject to certain pre-existing vendor agreements, for the treatment of prostate cancer in the U.S. and Canada.
There is a strong suspicion that Helicobacter pylori is linked to the development of stomach cancer. Now an international team of researchers led by Prof. Donald R. Ronning has used neutrons to unlock the secret to the functionality of an important enzyme in the bacterium's metabolism.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Sumatriptan Succinate Injection, USP, in two dosage strengths.
› Verified 2 days ago